An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness and safety of PROCRIT (Epoetin
alfa) at a starting dose of 60,000 Units (U) once every week (QW) to a target hemoglobin (Hb)
of 12 g/dL (Initiation Phase), followed by a dose of 80,000 Units once every three weeks
(Q3W) to maintain a Hb range of 11.5 to 12.5 g/dL (Maintenance Phase) in cancer patients
receiving chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.